A5101756946- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Erythropoietin and Anemia Treatment
- Monoclonal and Polyclonal Antibodies Research
- Renal cell carcinoma treatment
- Liver Disease and Transplantation
- Renal and related cancers
- Lymphoma Diagnosis and Treatment
- CRISPR and Genetic Engineering
- Biosimilars and Bioanalytical Methods
- Iron Metabolism and Disorders
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Liver Disease Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
Ghent University Hospital
2007-2023
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2007-2023
Allogene Therapeutics (United States)
2020-2022
Adaptimmune (United Kingdom)
2015-2019
Memorial Sloan Kettering Cancer Center
2019
Princess Margaret Cancer Centre
2019
Dana-Farber Cancer Institute
2019
City Of Hope National Medical Center
2019
City of Hope
2019
Cornell University
2019
Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations KRAS, small G-protein downstream EGFR, correlate poor response to anti-EGFR antibodies mCRC, their role as selection marker not been established randomized trials.
Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR). We compared activity of panitumumab plus best supportive care (BSC) to that BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemotherapy.We randomly assigned 463 1% or more EGFR tumor cell membrane staining, measurable disease, and radiologic documentation disease progression during within 6 months most recent chemotherapy mg/kg every 2...
Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- irinotecan-based) as first-line treatment for mCRC.Patients were randomly assigned within each cohort or without 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) oxaliplatin cohort. Tumor assessments performed 12 weeks reviewed...
To retrospectively evaluate the effectiveness of radiofrequency (RF) ablation hepatocellular carcinoma (HCC) by using histologic examination explanted liver.The study was approved medical center Institutional Review Board, with waiver informed consent. Forty-seven HCC nodules in 24 patients (18 men, six women; age range, 33-71 years; mean age, 56 years) were treated single or double RF sessions prior to liver transplantation. Histologic data from hematoxylin-eosin staining specimens reviewed...
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) recognizing HLA-A2-restricted NY-ESO-1/LAGE1a-derived peptide, in patients with metastatic synovial sarcoma (NY-ESO-1c259T cells). Confirmed antitumor responses occurred 50% (6/12) were characterized by tumor shrinkage over several months. Circulating NY-ESO-1c259T present postinfusion all persisted for at least 6 months responders. Most infused exhibited effector...
The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies.This phase 2 open-label, multicenter study enrolled who had progressed on chemotherapy that included a fluoropyrimidine irinotecan or oxaliplatin, both. All tumors > =10% 1+ epidermal growth factor receptor (EGFr) staining by immunohistochemistry. Patients were stratified into strata (high low intensity) received intravenous 2.5 mg/kg...
Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR)/platelet-derived (PDGFR)/c-Kit, is approved in locally advanced/metastatic renal cell carcinoma (RCC). Data from trials advanced solid tumours and RCC were used to explore the relationships between plasma pazopanib concentrations biomarker changes, safety, efficacy. Initially, pharmacokinetic parameters increased blood pressure investigated, followed by analysis of steady-state trough...
Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated clinical activity in patients with advanced synovial sarcoma (SS). The factors contributing to gene-modified expansion and changes within tumor microenvironment (TME) following infusion remain unclear. These studies address immunological mechanisms of response...
Abstract This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM) evaluated the safety and activity of autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) that recognizes a peptide shared by cancer antigens New York esophageal squamous cell carcinoma-1 (NY-ESO-1) L-antigen family member 1 (LAGE-1) presented HLA-A*02:01. collected from 25 HLA-A*02:01-positive MM expressing NY-ESO-1 and/or LAGE-1 were activated, transduced...
Abstract BACKGROUND: The authors explored the association of skin toxicity (ST) severity as measured by patient‐reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy panitumumab, a fully human antiepidermal growth factor receptor antibody, from phase 3 metastatic colorectal cancer (CRC) trial. METHODS: Patients were randomized to panitumumab plus best supportive care (BSC) vs BSC alone. modified National Cancer Institute CTCAE v3.0 Dermatology Life...
Abstract Purpose: This phase 1 study evaluated the safety, pharmacokinetics, and activity of panitumumab, a fully human, IgG2 monoclonal antibody that targets epidermal growth factor receptor in patients with previously treated receptor–expressing advanced solid tumors. Experimental Design: Sequential cohorts were enrolled to receive four i.v. infusions panitumumab monotherapy at various doses schedules. Safety was continuously monitored. Serum samples for pharmacokinetic, immunogenicity,...
In the United States, darbepoetin alfa (Aranesp) is often used to treat patients with chemotherapy-induced anemia using weekly or every-2-week administration schedules. Europe, either in every-3-week dosing. The schedule can be synchronized many chemotherapy regimens, resulting fewer visits and reducing burden patients, but safety efficacy of this regimen have not been clear.A randomized, double-blind, double-dummy, active-controlled phase 3 trial was performed 110 European centers. Eligible...
Abstract Background: Hepatocellular carcinoma (HCC) is one of the leading causes cancer related death worldwide. Liver resection or transplantation curative for a subset patients with localized disease, but treatments advanced disease are generally toxic and ineffective. Aberrant expression vascular endothelial growth factor (VEGF) has been implicated in progression HCC represents valid target anticancer therapy. Bevacizumab, humanized anti‐VEGF monoclonal antibody, currently being evaluated...
Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations KRAS, small G-protein downstream EGFR, correlate poor response to anti-EGFR antibodies mCRC, their role as selection marker not been established randomized trials.
Stimulation of vascular endothelial growth factor (VEGF) has been observed following transarterial chemoembolization (TACE) in hepatocellular cancer (HCC) and may contribute to tumor regrowth. This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE. 30 subjects with HCC undergoing TACE at single academic institution were randomized computer-generated allocation one ratio either bevacizumab dose 10 mg/kg...
De novo hepatocellular carcinoma (HCC) may have a large impact on patients waiting for liver transplantation. The presence of HCC can lead to status upgrade or removal from the waitlist. Our aim is compare costs and outcomes different cancer surveillance strategies. A Markov-based decision analytic model created simulate health hypothetical cohort awaiting transplantation undergoing screening. Three strategies screening are compared with referent strategy using alphafetaprotein (AFP) level...
To determine the effect of darbepoetin alfa (DA) on progression-free survival (PFS) and overall (OS) in patients with chemotherapy-induced anemia (CIA).Two 16-week randomized, double-blind, placebo-controlled phase III studies weekly DA anemic lung cancer (n = 314) or lymphoproliferative malignancies (LPMs; n 344) undergoing chemotherapy were analyzed prospectively defined long-term PFS OS end points. Short-term effects by including two additional dose-finding, multiple tumor types 405) LPMs...
3547 Background: Panitumumab is a fully human monoclonal antibody directed against EGFr. We investigated the antitumor activity of panitumumab in pts with mCRC who failed prior therapy and had low or negative EGFr tumor expression. Methods: In this multicenter, phase 2 study 150 planned pts, documentation disease progression (PD) during after adequate doses fluoropyrimidine, irinotecan, oxaliplatin (centrally confirmed refractory [CCRD]), 2–3 regimens, ECOG score 0–2, staining (by IHC)...
A chromosome 14 inversion was found in a patient who developed bone marrow aplasia following treatment with allogeneic chimeric antigen receptor (CAR) Tcells containing gene edits made transcription activator-like effector nucleases (TALEN). TALEN editing sites were not involved at either breakpoint. Recombination signal sequences (RSSs) suggesting recombination-activating (RAG)-mediated activity. The represented dominant clone detected the context of decreasing absolute CAR Tcell and...